2 hours ago
1
Welcure Drugs & Pharmaceuticals Ltd (BSE: 524661) in the board of directors meeting held on August 22 has considered and approved a bonus and stock split. Following the company’s stellar Q1FY26 financial results, this move is aimed at enhancing liquidity and broadening shareholding.
Highlights:
|
1:10 Bonus Issue
The Board has considered and approved the issue of bonus shares in the ratio of 1:10 (one bonus equity share of Rs 10 each for every 10 equity shares of Rs 10 each) to the eligible equity shareholders of the company as on the proposed record date by capitalization of securities premium, subject to the approval of the shareholders of the company. A total of 1,12,35,820 equity shares will be issued as bonus shares. The bonus shares would be credited within two months of the date of the board approval.
As of June 30, 2025, the company has free reserves amounting to Rs 13.37 crore. Post-bonus issue paid-up share capital: 12,35,94,020 equity shares of face value of Rs 10 each aggregating to share capital of Rs 123.59 crore. The issuance of bonus shares will be carried out of the securities premium received in cash and/or free reserve and/or retained earnings of the company, subject to the approval of the shareholders.
10:1 Stock Split
The board of directors also considered and approved a 10:1 stock split. One equity share of the face value of Rs 10 each will be subdivided/split into 10 equity shares of the face value of Re 1 each, subject to the approval of equity shareholders of the company through postal ballot.
The stock split is aimed at enhancing the liquidity of the company's shares in the market and making them more accessible to retail investors. The record date for the sub-division/split of existing equity shares shall be decided after taking the aforesaid approval of the equity shareholders of the company. The stock split is expected to be completed within two months.
Increase Authorised Share Capital
The board also considered and approved the increase in the authorised share capital of the company from Rs 186 crore to Rs 196 crore in the board meeting on August 22, which is subject to the approval of the members.
|
Welcure Drugs & Pharmaceuticals Ltd to set up a state-of-the-art agro pharma research laboratory; it will invest Rs. 70-80 crore in the project Welcure Drugs & Pharmaceuticals Ltd (BSE: 524661) is planning to invest around Rs. 70-80 crore in setting up a state-of-the-art cGMP standard research laboratory dedicated to agro-pharma research. The size of the project is estimated to be around Rs. 70-80 crore, including laboratory infrastructure, pilot lines, analytics and quality systems. The facilities and processes will be designed to align with applicable cGMP standards and the US FDA’s botanical drug development guidance (as relevant), in order to enable participation in broader international markets for botanical/ayurvedic products, subject to all necessary approvals. The proposed site, timeline and commissioning plan will be finalised post approvals. The company proposes to raise up to Rs. 80 crore by way of Qualified Institutional Placement (QIP), in one or more tranches, to fund the agro-pharma research laboratory and for general corporate purposes. The meeting of the board of directors will be held on August 28, 2025, to consider and, if deemed appropriate, approve the aforesaid fund-raising by QIP, including approving enabling resolutions, issue structure and seeking shareholders’ approval as may be required. The objective of the laboratory will be to research, validate and scale processes for the conversion of agricultural/botanical inputs into pharma-grade products aimed at public health and societal wellbeing. The above proposals are subject to requisite Board, shareholder, regulatory and statutory approvals and market conditions. The company is planning to invest around Rs. 70-80 crore in setting up a state-of-the-art cGMP standard research laboratory dedicated to agro-pharma research, including laboratory infrastructure, pilot lines, analytics & quality systems. |
These proposals are part of Welcure’s commitment to enhancing market liquidity, expanding retail participation, and improving affordability for investors. These proposals are subject to the board’s decision and subsequent statutory/shareholder approvals. If approved, the company will announce record dates and implementation timelines separately, in accordance with SEBI Listing Obligations and Disclosure Requirements (LODR) and applicable laws.
Speaking on this development, the company management commented, “As a part of our evolving business strategies, we have come up with this proposal for Stock Split and Bonus Issue. These proposals reflect our confidence in Welcure’s growth trajectory and our commitment to enhancing shareholder value. Coupled with our strong financial results and asset-light business model, these steps aim to make Welcure’s shares more accessible and liquid in the market.”
Excellent Q1FY26 Results –
Recently, the company announced its Q1FY26 financial results. Driven by its strategic foray into fee-based export-oriented sourcing services, the company’s revenue from operations rose sharply to Rs. 299.91 crore in Q1FY26, up from Rs. 21.21 crore in Q4FY25. This represents growth of around 1300% QoQ. Net Profit surged to Rs. 23.29 crore from Rs. 2.50 crore in Q4FY25, marking an 830% increase.
Previously, the company completed seven export-sourcing assignments totalling Rs. 299.91 crore, earning fixed commission income with no inventory or logistics exposure, maintaining its debt-free status. In addition, a Rs. 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited is expected to generate approximately Rs. 25.85 crore in service income during FY26.
About Welcure Drugs & Pharmaceuticals Ltd:
Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.
This article is from the Brand Desk. User discretion is advised.
English (US) ·